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Abstract
Summary The cytokine interferon gamma (IFN-γ) stimulates
neopterin release and tryptophan degradation into
kynurenines through the kynurenine pathway. High levels of
neopterin were associated with increased hip fracture risk, as
were some of the kynurenines, suggesting a role of IFN-γ-
mediated inflammation in the processes leading to hip
fracture.
Introduction Low-grade systemic inflammation has been as-
sociated with bone loss and risk of fractures. Interferon gam-
ma (IFN-γ) initiates macrophage release of neopterin and also
stimulates degradation of tryptophan along the kynurenine
pathway as part of cell-mediated immune activation. Plasma
neopterin and the kynurenine/tryptophan ratio (KTR) are thus
markers of IFN-γ-mediated inflammation. Risk of hip fracture
was investigated in relation to markers of inflammation and
metabolites in the kynurenine pathway (kynurenines).
Methods Participants (71 to74 years, N=3,311) in the
community-based Hordaland Health Study (HUSK) were
followed for hip fractures from enrolment (1998–2000) until
31 December 2009. Plasma C-reactive protein (CRP),
neopterin, KTR, and six kynurenines were investigated as
predictors of hip fracture, using Cox proportional hazards
regression analyses.
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Results A hazard ratio (HR) of 1.9 (95 % confidence interval
(CI) 1.3–2.7) for hip fracture was found in the highest com-
pared to the lowest quartile of neopterin (p trend across
quartiles <0.001). CRP and KTR were not related to hip
fracture risk. Among the kynurenines, a higher risk of fracture
was found in the highest compared to the lowest quartiles of
anthranilic acid and 3-hydroxykynurenine. For subjects in the
highest quartiles of neopterin, CRP, and KTR compared to
those in no top quartiles, HR was 2.5 (95 % CI 1.6–4.0).
Conclusions This may indicate a role for low-grade immune
activation in the pathogenic processes leading to hip fracture.
Keywords Hip fracture . Inflammation . Kynurenine
pathway . Neopterin . Osteoimmunology . Osteoporosis
Introduction
Patients with inflammatory diseases are known to have higher
risk of osteoporosis and fractures [1], and even low-grade sub-
clinical systemic inflammation has been associated with low
bone mineral density (BMD) [2]. High serum levels of proin-
flammatory cytokines, cytokine-soluble receptors [3, 4], and
C-reactive protein (CRP) [5–9] have been associated with
increased risk of fractures, although the findings are ambigu-
ous for some of the inflammatory markers [3, 4].
The immune system influences differentiation and activity
of bone cells within the bonemicroenvironment [1]. CRP is an
acute phase reactant produced in response to cytokine release
during inflammation, and high-sensitivity (hs) CRP allows
assessment of low-grade inflammation. Interferon gamma
(IFN-γ) is a major stimulator of cell-mediated immune acti-
vation [10] and differentiation of T cells and macrophages. In
vitro and animal studies indicate a dual effect of IFN-γ on
bone. In normal bone remodeling, IFN-γ may improve bone
mass [11] and decrease bone degradation by blunting osteo-
clast formation [1]. In mouse models of inflammatory states,
IFN-γ enhances bone degradation e.g., via stimulation of T
cell secretion of the receptor activator of NF-κB ligand
(RANKL) and tumor necrosis factor α [12]. In humans,
IFN-γ has been used to increase bone resorption in patholog-
ically dense bone tissue (osteopetrosis) [1]. Results from a few
[13–15], but not all [16] studies have indicated an association
between IFN-γ or gene variants influencing IFN-γ level, with
osteoporosis and fracture risk.
In a state of immune activation, IFN-γ stimulates macro-
phages to release neopterin [17], which due to its stability in
body fluids is used as an index of IFN-γ-mediated inflamma-
tion [10] and for the assessment of disease activity in several
conditions [10]. Further, IFN-γ stimulates the indoleamine
dioxygenase (IDO) enzyme [18], initiating degradation of
the essential amino acid tryptophan through the kynurenine
pathway into metabolically active compounds known as
kynurenines (Fig. 1). IDO and the kynurenines are increas-
ingly recognized as important regulators of the immune sys-
tem, e.g., by modulating the function of regulatory Tcells [18,
19]. Some kynurenines are powerful regulators of oxidative
stress as well, having both pro- and anti-oxidant abilities [20].
Kynurenine is the initial degradation product of tryptophan
through the kynurenine pathway, and the kynurenine/
tryptophan ratio (KTR) is a marker of IDO activity and cell-
mediated inflammation [18]. Increased KTR has been related
to neurological and mental conditions [21], as well as to
cardiovascular [22] and renal disease [23]. A possible relation
between neopterin or the kynurenines and risk of hip fractures
has not previously been reported.
We have earlier reported inverse associations between
BMD and IFN-γ-mediated inflammation and positive associ-
ations with some metabolites of the kynurenine pathway [24].
The aim of the present study was to extend our previous
findings by further examining IFN-γ-associated inflammation
markers and kynurenines, in addition to hs-CRP, as predictors
of hip fracture.
Materials and methods
Subjects
The community-based Hordaland Health Study (HUSK) was
conducted in the city of Bergen and three neighboring munic-
ipalities, and cohort inclusion took place from April 1998 to
June 1999. Subjects born during 1925–27 who had previously
participated in the Hordaland Homocysteine Study 1992–93
were invited (N=4,338). Of these, 3,341 met for the study and
answered questionnaires. Blood samples were analyzed from
3,311 participants (76.3 % of those invited). The Regional
Committee for Medical Research Ethics and the Norwegian
Data Inspectorate approved the study protocol, and all partic-
ipants signed an informed consent. The study was performed
according to the principles of the Declaration of Helsinki of
the World Medical Association.
Blood samples
Non-fasting blood samples were drawn and stored in EDTA-
containing tubes, which were chilled within 15–30 min and
then centrifuged. Unfrozen plasma samples were transported
to the laboratory, usually arriving within 1 day, always within
4 days. The samples were frozen at −80 °C and stored for up to
13 years before analysis [25]. Plasma analyses of tryptophan
and the kynurenines (kynurenine, kynurenic acid, anthranilic
acid, 3-hydroxykynurenine, xanthurenic acid, and 3-
hydroxyanthranilic acid), neopterin, and cotinine (a nicotine
metabolite used as a biomarker of recent nicotine exposure)
were performed using liquid chromatography-tandem mass
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spectrometry (LC/MS/MS) at Bevital A/S (www.bevital.no/),
Bergen, Norway [26]. Studies of stability and deterioration
kinetics indicate that the studied biomarkers are stable under
these conditions [27, 28].
Sensitive C-reactive protein EDTA plasma levels were
determined at Bevital A/S by a novel immuno-assay based
on matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS).
Hip fractures
A hip fracture was defined as the first fracture of the proximal
femur occurring during the observation period between base-
line and 31 December 2009. Information on hip fractures was
obtained from the hospitals serving Hordaland County, using
a computerized search of discharge diagnosis records. Only
hip fractures confirmed by a concurrent code of an adequate
surgical procedure code were included, as previously de-
scribed [29] and validated [30]. The discharge diagnoses used
to classify a hip fracture were according to the International
Classification of Diseases, Ninth Revision (ICD-9): 820–
820.9 and Tenth Revision (ICD-10): S720-S722. Surgical
treatments for each hospital stay were coded according to
the Norwegian Classification of Surgical Procedures (version
2, 1989 and 3, 1995) and later the Nordic Medico-Statistical
Committee (NOMESCO) Classification of Surgical Proce-
dures (version 1, 1999- version 3, 2004). The Norwegian
Population Register provided information on time of death.
Follow-up time was from enrolment until first hip fracture,
death or 31 December 2009.
Additional data
Self-administered questionnaires provided information on
health status, use of medication, sociodemographic data, and
lifestyle factors. Use of disease-modifying anti-rheumatic
drugs (DMARDs) was included in some of the analyses as a
marker of inflammatory rheumatic disease. Reported use of
DMARDSs included methotrexate, sulfasalazine,
hydroxychloroquine, cyclosporine, auranofin, and penicilla-
mine. Use of non-steroidal anti-inflammatory drugs
(NSAIDs) was included in supplementary analyses to study
any effect of these medications on the relation between in-
flammatory markers and hip fractures.
Height and weight were measured in light clothing, and
body mass index (BMI; kg/m2) calculated. BMD was mea-
sured by dual X-ray densitometer (EXPERT-XL; Lunar Com-
pany Inc,Madison,WI, USA, software version 1.72 and 1.90)
in a subgroup of 2,221 participants as described earlier [24].
Fig. 1 The kynurenine pathway
of tryptophan metabolism.
Degradation of the essential
amino acid tryptophan through
the kynurenine pathway is
initiated by either indoleamine
2,3-dioxygenase or by tryptophan
dioxygenase (TDO). TDO is
primarily found in the liver and is
induced by tryptophan and
corticosteroids, whereas IDO is
an ubiquitous enzyme induced by
cytokines. AMO anthranilate
monooxygenase, KAT
kynurenine aminotransferase,
KMO kynurenine
monooxygenase, KYNU
kynureninase
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Statistical analyses
Distribution of continuous variables is reported as means and
standard deviations (SD) for normally distributed variables, or
medians and interquartile range for skewed distributions.
Counts (percentages) are reported for categorical variables.
Subjects with and without later hip fractures were compared
within each sex, using the independent t tests for continuous
variables and the exact chi-square test for categorical
outcomes.
Nicotine exposure (cotinine) was categorized into no, light,
or heavy exposure for the baseline characteristics table, but
cotinine was used as a continuous variable in the analyses.
Use of corticosteroids, DMARDs, and NSAIDs was dichoto-
mized into present use or no use. Renal functionwas estimated
by glomerular filtration rate (eGFR) using the Modification of
Diet in Renal Disease (MDRD) formula [31] and was dichot-
omized according to normal (60 mL/min or above) or reduced
(below 60 mL/min) renal function.
Correlations between CRP, neopterin and KTR in the
whole cohort were assessed by Spearman’s rho (rs).
Cox proportional hazards model was used to estimate the
associations between serum neopterin, KTR, tryptophan, and
kynurenines (continuous and categorized into quartiles) and risk
of subsequent hip fracture. Analyses using quartiles of the
inflammatory markers and kynurenines are reported, as well as
p for trend across quartiles. Multicollinearity between covariates
and interactions between covariates and time were tested. The
multivariable model includes sex, BMI, cotinine, and eGFR.
A composite measure was constructed by combining those
being in the highest quartile of all the three inflammatory
markers (CRP, neopterin, and KTR), the highest quartile of
two (CRP and neopterin, or CRP and KTR), one or none, and
the risk of hip fracture was examined using Cox regression
analyses.
Significance level of 0.05 was chosen for all statistical
tests. The statistical package SPSS (version 18 for Windows,
Chicago, IL, USA) was used. Venn diagram was created using
Google (https://developers.google.com/chart/image/docs/
chart_wizard).
Results
Follow-up data and baseline characteristics
Median follow-up time was 10.8 years (range 0.01–11.7), and
a hip fracture during follow-up was recorded among 277
(8.4 %) of the participants. Baseline characteristics are shown
and compared according to hip fracture status within each sex
in Table 1. No differences in factors related to health or
lifestyle were found among men, but those later suffering a
hip fracture had higher neopterin and anthranilic acid levels.
Women with a hip fracture during follow-up had lower base-
line BMI and a higher exposure to nicotine. No significant
differences in inflammation markers or kynurenines were
found among women with and without a later hip fracture.
Correlations
A positive correlation was found between CRP and neopterin
(rs=0.19, p<0.001), CRP and KTR (rs=0.22, p<0.001), and
neopterin and KTR (rs=0.52, p<0.001).
Inflammation markers, kynurenines, and risk of hip fracture
Cox proportional hazards regression analyses of risk of hip
fractures were performed according to quartiles of CRP,
neopterin, KTR, tryptophan, and kynurenines as shown in
Table 2. A statistically significant prediction of hip fracture
was found for neopterin and tryptophan after adjustment for
sex. In the fully adjusted model (adjustment for sex, BMI,
cotinine, and eGFR), a significant higher risk of hip fracture
was found in the highest compared to the lowest quartiles of
neopterin, anthranilic acid, and 3-hydroxykynurenine, with a
significant trend across quartiles. The estimates were mostly
unchanged after additional adjustment for use of corticoste-
roids and DMARDs, and there were no major changes after
adjusting for use of NSAIDs. Levels of CRP and KTR were
not associated with risk of hip fracture.
Additional analyses for anthranilic acid and 3-
hydroxykynurenine as continuous variables in relation to risk
of hip fracture were done. Anthranilic acid was not signifi-
cantly associated with hip fracture in analysis adjusting for sex
only (p=0.060), but significantly associated in the model
adjusted for sex, BMI, cotinine, and eGFR (p=0.003). A
statistically significant association was also found between
3-hydroxykynurenine and risk of hip fracture (p=0.033 ad-
justed for sex, p=0.001 in the multiple adjusted model).
Cox proportional hazards regression analyses were also
performed for risk of hip fracture in relation to the inflamma-
tory markers and the kynurenines with additional adjustment
for BMD among the 2,221 participants with BMD measure-
ment, but this did not materially change the estimates.
Cox regression analyses were performed for men and
women combined. However, an interaction between sex and
neopterin was found for risk of hip fracture (p interaction=
0.021), with hazard ratio (HR) 3.23 (95 % confidence interval
(CI) 1.69–6.19) for men in the highest compared to the lowest
neopterin quartile (p trend across quartiles <0.001), and HR
1.48 (CI 0.99–2.22) among women (p trend=0.069). No
interaction was found between sex and CRP, KTR, or
kynurenines in relation to risk of hip fracture.
Subjects in the highest quartile (Q4) of all three inflamma-
tory markers (CRP, neopterin, and KTR) (n=171, constituting
5 % of the cohort) had a higher risk of hip fracture compared
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to those not being in Q4 of any of the inflammatory markers
(n=1,638) (Fig. 2), with HR 2.51 (CI 1.59–3.98) adjusted for
sex, cotinine, BMI, and eGFR (p trend<0.001 according to
being in the highest quartile of one, two, or three markers).
The distribution of participants according to any combination
of the highest quartile of one, two, or all three inflammatory
markers is shown in Fig. 3.
Discussion
In this study, we investigated CRP and the IFN-γ-induced
inflammation markers neopterin and KTR, as well as
kynurenines, in relation to risk of hip fracture. A higher risk
of hip fracture among subjects in the highest compared to the
lowest quartiles of neopterin, anthranilic acid, and 3-
hydroxykynurenine was found, after adjustment for sex,
BMI, cotinine, and renal function. These findings persisted
after additional adjustment for BMD in a subgroup analysis.
Further, we found that participants in the top quartiles of all
three inflammatory markers (CRP, neopterin, and KTR) had a
2.5-fold higher risk of hip fracture compared to those with no
inflammatory marker in the highest quartile.
Plasma concentrations of all the kynurenines were similar
to those obtained in fresh samples indicating acceptable con-
ditions for blood sample collection and storage [27]. Levels of
neopterin, tryptophan, and kynurenine were comparable to
those found in other studies [22, 32], as were correlations
between the inflammatory markers CRP, neopterin, and
KTR [21, 22, 33].
Strengths of the study include the large size of the cohort,
the long follow-up time, as well as the comprehensive
Table 1 Baseline characteristics 1998–99 in 3,311 women andmen (71–74 years old), stratified by hip fracture during follow-up. The Hordaland Health
Study
Men Women
No hip fracture
(n =1,369)a
Hip fracture
(n=86)a
p valueb No hip fracture
(n =1,665)a
Hip fracture
(n =191)a
p valueb
BMI, mean (SD) 26.0 (3.2) 25.8 (3.5) 0.556 26.4 (4.4) 24.8 (4.2) 0.001
eGFR below 60 mL/min, n (%) 273 (20.0) 19 (22.1) 0.677 928 (55.7) 92 (48.2) 0.055
Current use of corticosteroids, n (%) 22 (1.6) 3 (3.5) 0.180 34 (2.0) 7 (3.7) 0.185
Current use of DMARD, n (%) 11 (0.8) 2 (2.3) 0.177 21 (1.3) 5 (2.6) 0.179
Current use of NSAID, n (%) 35 (2.6) 2 (2.3) 0.999 111 (6.7) 15 (7.9) 0.543
Current use of estrogen, n (%) NA NA 176 (14.5) 21 (15.4) 0.798
Cotinine, n (%)c 0.149 0.001
<85 nmol/L (light nicotine exposure) 1,100 (80.4) 62 (72.1) 1,409 (84.6) 144 (75.4)
85–1,000 nmol/L (moderate nicotine exposure) 89 (6.5) 8 (9.3) 131 (7.9) 16 (8.4)
>1,000 nmol/L (heavy nicotine exposure) 180 (13.1) 16 (18.6) 125 (7.5) 31 (16.2)
Cotinine (nmol/L), median (IQR)d 0.9 (9.9) 1.3 (586.3) 0.081 0.4 (3.4) 0.9 (25.9) 0.001
Inflammation markers
CRP (μg/mL), median (IQR) 2.2 (3.4) 2.3 (4.9) 0.441 2.1 (3.4) 2.2 (3.7) 0.605
Neopterin (nmol/L), median (IQR) 8.6 (3.3) 9.6 (5.2) 0.003 8.7 (3.3) 8.8 (4.1) 0.809
Kynurenine/tryptophan ratio, median (IQR) 26.1 (10.1) 27.5 (11.1) 0.172 26.3 (10.1) 26.1 (11.4) 0.863
Kynurenines
Tryptophan (μmol/L), median (IQR) 68.2 (18.3) 64.3 (19.6) 0.117 62.6 (17.8) 61.2 (17.1) 0.102
Kynurenine (μmol/L), median (IQR) 1.8 (0.6) 1.8 (0.7) 0.913 1.7 (0.6) 1.6 (0.6) 0.148
Kynurenic acid (nmol/L), median (IQR) 54.6 (27.3) 53.5 (38.8) 0.452 48.2 (24.9) 46.9 (27.5) 0.466
Anthranilic acid (nmol/L), median (IQR) 16.7 (7.3) 19.0 (9.3) 0.028 15.9 (6.8) 16.1 (7.2) 0.549
3-Hydroxykynurenine (nmol/L), median (IQR) 36.2 (15.3) 37.0 (19.7) 0.480 35.3 (15.8) 35.1 (17.1) 0.386
Xanthurenic acid (nmol/L), median (IQR) 16.6 (11.0) 16.3 (10.3) 0.515 14.1 (9.1) 13.4 (8.4) 0.054
3-Hydroxyanthranilic acid (nmol/L), median (IQR) 36.0 (18.0) 33.1 (22.7) 0.949 32.8 (16.4) 32.1 (16.4) 0.522
BMI body mass index, CRP C-reactive protein, DMARD disease-modifying anti-rheumatic drug, eGFR estimated glomerular filtration rate, IQR
interquartile range, NSAID non-steroidal anti-inflammatory drug, NA not applicable, SD standard deviation
a Total numbers may vary between variables due to missing data
b Groups with and without hip fracture compared within each sex by independent samples t test (continuous data) or the exact chi-square test (categorical
data)
c Cotinine compared as categorical variable
d Cotinine compared as continuous variable
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laboratory analyses performed at the same laboratory. Data on
medication may have been insufficient as participants were
only asked about medications taken the previous day. Con-
centrations of biomarkers and data on potential confounders
were obtained at baseline and not repeated during follow-up.
However, the biomarkers have sufficient reproducibility
(intraclass correlation coefficient over 2–3.5 years in the range
0.5–0.7) to allow one-exposure assessment of biomarker sta-
tus [28].
KTR and the kynurenines are earlier found to be associated
with BMI [34], smoking [34, 35], and renal function [23, 34].
These factors are confounders in the relation between
kynurenines and osteoporosis/fracture risk [36–38] and were
therefore adjusted for.
CRP levels were not significantly associated with risk of
hip fractures in the present study. This was somewhat unex-
pected, as an association between CRP and low-trauma frac-
tures has previously been reported [5–7, 9]. To our knowl-
edge, risk of hip fractures separately in relation to CRP has
only been investigated in one study [39], demonstrating no
significant association.
We found that the IFN-γ-mediated inflammation marker
neopterin was associated with an increased risk of hip fracture.
A higher IFN-γ production in peripheral blood mononuclear
cells has been reported for postmenopausal women with verte-
bral fractures, compared to controls [13], and experimental
studies have indicated a role of IFN-γ in postmenopausal bone
loss [40]. However, we are aware of no previous studies on
plasma neopterin and fracture risk. Due to the complexity of the
immunologic pathways involved in inflammation, combining
different markers may better reflect overall activation of the
immune system than one single inflammatory marker. An
enhanced prediction of fracture risk by combining inflamma-
tory markers has been reported for other studies as well [3, 4].
The observed association between inflammation assessed
by neopterin and risk of fracture was independent of BMD.
This is in agreement with earlier studies [4–7, 9], suggesting
an impact of inflammation on bone microarchitecture and
bone strength [5, 8], or the finding could possibly be explained
by other factors such as reduced muscle strength, impaired
balance, or impaired nutritional status.
In the present s tudy, anthrani l ic acid and 3-
hydroxykynurenine were associated with an increased risk
of hip fracture. We are not aware of previous studies on
kynurenines in relation to fracture risk, but the finding is in
accordance with one other study describing increased levels
Table 2 Risk of hip fracture by Cox proportional hazard model according to quartiles (Q1 lowest–Q4 highest) of inflammation markers and metabolites
of the kynurenine pathway in 71–74 years old women and men. The Hordaland Health Study
n Model Q1 Q2 HR (CI) Q3 HR (CI) Q4 HR (CI) p trenda
CRP 3,198 Model 1 1.00 (ref) 0.91 (0.65, 1.29) 0.95 (0.68, 1.34) 1.08 (0.77, 1.50) 0.638
Model 2 1.00 (ref) 1.00 (0.71, 1.42) 1.06 (0.75, 1.51) 1.28 (0.91, 1.81) 0.160
Neopterin 3,311 Model 1 1.00 (ref) 1.06 (0.74–1.52) 1.17 (0.83–1.66) 1.70 (1.22–2.36) 0.001
Model 2 1.00 (ref) 1.08 (0.76–1.55) 1.23 (0.86–1.75) 1.88 (1.34–2.65) 0.001
KTR 3,289 Model 1 1.00 (ref) 0.80 (0.57–1.12) 0.85 (0.61–1.19) 1.10 (0.80–1.51) 0.515
Model 2 1.00 (ref) 0.85 (0.60–1.19) 1.00 (0.71–1.41) 1.31 (0.94–1.82) 0.087
Tryptophan 3,311 Model 1 1.00 (ref) 0.95 (0.70–1.30) 0.64 (0.46–0.91) 0.73 (0.53–1.02) 0.013
Model 2 1.00 (ref) 1.04 (0.76–1.42) 0.71 (0.50–1.01) 0.81 (0.58–1.13) 0.065
Kynurenine 3,289 Model 1 1.00 (ref) 0.78 (0.56–1.09) 0.87 (0.62–1.20) 0.94 (0.68–1.31) 0.863
Model 2 1.00 (ref) 0.88 (0.63–1.23) 1.05 (0.75–1.47) 1.25 (0.89–1.77) 0.146
Kynurenic acid 3,311 Model 1 1.00 (ref) 0.72 (0.52–1.01) 0.70 (0.50–0.97) 0.91 (0.66–1.25) 0.500
Model 2 1.00 (ref) 0.80 (0.58–1.12) 0.83 (0.59–1.17) 1.19 (0.85–1.66) 0.398
Anthranilic acid 3,289 Model 1 1.00 (ref) 0.85 (0.60–1.20) 1.00 (0.72–1.40) 1.20 (0.87–1.66) 0.170
Model 2 1.00 (ref) 0.96 (0.67–1.36) 1.24 (0.87–1.75) 1.48 (1.06–2.08) 0.009
3-Hydroxykynurenine 3,310 Model 1 1.00 (ref) 1.14 (0.82–1.59) 0.90 (0.63–1.27) 1.29 (0.93–1.79) 0.30
Model 2 1.00 (ref) 1.26 (0.90–1.76) 1.04 (0.73–1.49) 1.63 (1.15–2.30) 0.022
Xanthurenic acid 3,310 Model 1 1.00 (ref) 1.09 (0.79–1.50) 0.88 (0.63–1.24) 0.82 (0.59–1.16) 0.15
Model 2 1.00 (ref) 1.17 (0.85–1.62) 1.08 (0.73–1.43) 1.00 (0.70–1.42) 0.80
3-Hydroxyanthranilic acid 3,310 Model 1 1.00 (ref) 0.82 (0.59–1.14) 0.73 (0.52–1.02) 0.87 (0.63–1.20) 0.31
Model 2 1.00 (ref) 0.94 (0.68–1.31) 0.87 (0.62–1.22) 1.10 (0.79–1.53) 0.73
Model 1: adjusted for sex
Model 2: adjusted for sex, body mass index, cotinine, eGFR (estimated glomerular filtration rate over/below 60 mL/min)
CI 95 % confidence interval, CRP C-reactive protein, HR hazard ratio, KTR kynurenine/tryptophan ratio, Q1–Q4 quartiles 1 to 4
a Across quartiles
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of anthranilic acid in osteoporotic patients compared to
controls [41].
Our knowledge of the immune system has evolved from
the idea of a mere protector against invading organisms to an
Fig. 3 Venn diagram showing
the distribution of participants in
the Hordaland Health Study
according to inflammatory status
assessed as any combination of
inflammatory markers in the
upper quartile of each marker. Of
the 3,178 participants with
measurements of all three
inflammatory markers, 1,638
(51.5 %) persons were not in the
highest quartile of any of the
inflammatory markers. The
correct proportional overlap
between the inflammatory
markers is shown, and numbers
show percentages of the total
cohort
Fig. 2 Kaplan-Meier survival
curves for time to hip fracture in
3,178 men and women
(71–74 years at inclusion),
stratified on subjects in the
highest quartiles of none
(n=1,638), one (n=879), two
(n=490), or three (n=171)
inflammation markers (CRP,
neopterin, kynurenine/tryptophan
ratio). The Hordaland Health
study
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increasing understanding of its cruciate role in physio-
logical processes, including differentiation and stimula-
tion of bone cells [1]. CRP release is mainly elicited by
interleukin-6 (IL-6) [42], one of several cytokines induc-
ing release of RANKL [1], the main stimulator of bone
degradation. IFN-γ has been found to stimulate osteo-
clast formation in states of immune activation through
T cell RANK signaling [12]. T cell RANKL expression
has, however, not been found as an important stimulator
of bone resorption in non-inflammatory conditions [43].
In contrast, murine studies have shown that IFN-γ is
essential for development of normal bone structure under
physiological conditions [11]. IFN-γ also reduces bone
resorption in vitro by inhibiting the ability of 1,25-
dihydroxyvitamin D3, parathyroid hormone, and IL-1 to
stimulate the formation of osteoclast-like cells [1].
Higher expression of IFN-γ-related genes in human hip
bone samples from osteoarthritic compared with osteo-
porotic patients has been reported [16], which is not in
agreement with our earlier and present findings indicat-
ing an association between IFN-γ-stimulated inflamma-
tion and increased risk of low BMD and hip fracture
[24]. This may illustrate a difference in local and sys-
temic effects.
3-Hydroxykynurenine has both pro- and anti-oxidative
properties [20, 44] and was associated with risk of hip fracture
in the present study. An increase in reactive oxygen species
has been linked to higher bone resorption [45]. The associa-
tion between 3-hydroxykynurenine and an increased risk of
hip fracture in the present study may also be related to a
positive association between 3-hydroxykynurenine and in-
flammatory markers [33].
In this study, we found that the inflammation marker
neopterin was positively associated with risk of hip frac-
ture, while CRP and KTR were not. This may possibly
reflect a greater impact of IFN-γ-mediated inflammation
on fracture risk than components of the innate immune
system as measured by CRP. Further, high levels of
anthranilic acid and 3-hydroxykynurenine were also asso-
ciated with increased risk of hip fracture. Although these
findings may suggest an association between INF-γ-
mediated inflammation and risk of hip fractures, addition-
al studies are required to explore the role of IDO and
kynurenines in bone metabolism.
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